<html><body><pre>[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[S. 2512 Enrolled Bill (ENR)]

        S.2512

                     One Hundred Fourteenth Congress

                                 of the

                        United States of America


                          AT THE SECOND SESSION

           Begun and held at the City of Washington on Monday,
           the fourth day of January, two thousand and sixteen


                                 An Act


 
 To expand the tropical disease product priority review voucher program 
                 to encourage treatments for Zika virus.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
    This Act may be cited as the ``Adding Zika Virus to the FDA 
Priority Review Voucher Program Act''.
SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER 
PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS DISEASE.
    Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360n(a)(3)) is amended--
        (1) by redesignating subparagraph (R) as subparagraph (S);
        (2) in subparagraph (Q), by striking ``Filoviruses'' and 
    inserting ``Filovirus Diseases''; and
        (3) by inserting after subparagraph (Q) the following:
            ``(R) Zika Virus Disease.''.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
</pre></body></html>
